HIV incidence among sexually active young males and females in Kisumu County, Western Kenya Authors: John Owuoth, Chiaka Nwoga, Valentine Sing’oei, Adam Yates, June Otieno, Erica Broach, Qun Li, Zebiba Hassen, Seth Frndak, Michelle Imbach, Leigh Anne Eller, Mark Milazzo, Tsedal Mebrahtu, Hunter J. Smith, Nathanial K. Copeland, Jessica Cowden, Dale J. Hu, Merlin L. Robb, Julie A. Ake, Christina S. Polyak, Trevor A. Crowell, on behalf of the RV393 Study Group, Darrell Singer, Darrell Singer Published: 2026 ABSTRACT IntroductionHIV prevalence in Kisumu County, Kenya, is over four times the national average. We estimated HIV incidence among adults with multiple sexual partners and identified risk factors associated with HIV acquisition.MethodsWe enrolled adults aged 18–35 years reporting ≥2 sexual partners in the prior 3 months, recruiting primarily from villages with fisherfolk. HIV counseling and testing were performed every 3 months for up to 24 months. Demographic, health, sexual, and behavior questionnaires were administered every 6 months. Enrollment characteristics were compared between participants who did and did not acquire HIV using chi-squared tests. Bivariable Cox proportional hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for potential risk factors.ResultsBetween January 2017 and August 2021, 619 participants without HIV were enrolled, of whom 45% were female, 47% were ≥25 years old, 66% were single or widowed, and 46% had some secondary education. Eleven HIV seroconversions occurred over 1117.9 person-years (PY; incidence 9.84/1000 PY [95% CI: 5.22–17.03]), including eight in the first year of follow-up (13.84/1000 PY). Risk factors in unadjusted analyses included ≥4 sexual partners (HR 4.39 [95% CI 1.10-17.55]) and forced sexual activity (HR 9.15 [95% CI 1.17-71.51]).ConclusionHIV incidence was lower than expected, possibly reflecting prevention efforts or COVID-19-related behavior changes. Lower incidence in later follow-up may indicate a cohort effect from regular counseling. Increasing ART coverage and pre-exposure prophylaxis may have decreased HIV incidence in fishing communities of Western Kenya. Background An estimated 1.5 million people acquired HIV worldwide in 2021, with 51% of all new cases globally occurring in sub-Saharan Africa. Though this region bears a disproportionate burden of HIV compared to other parts of the world, there has been a regional decline in HIV incidence since 2010 [1,2]. Kenya has the fifth highest total number of people living with HIV with a prevalence of 4% among the adult population [3,4]. HIV is a leading cause of adult morbidity and mortality in the region [5–7]. In Kenya, HIV prevalence varies by county and Kisumu County is among the top 5 high-burden counties with a prevalence of 17.5%, which is more than four times the national average [8,9]. Kisumu County is one of 47 counties in Kenya and is further subdivided into seven sub-counties. It is in the western part of the country bordering Lake Victoria, the largest lake in Africa. Development of novel HIV interventions requires monitoring epidemic spread, evaluating HIV prevention and treatment strategies, and assessing changes in characteristics of populations affected by HIV, particularly if demographic or geographic data may inform the HIV response [10,11]. The annual incidence of HIV among adults aged 15–64 years in Kenya is approximately 0.14% and an estimated 36,000 youths aged 15–24 years acquire HIV each year. Youth account for 42% of new HIV cases in people aged 15 years and older in the country [12–14]. Factors associated with HIV acquisition include multiple sexual partners, condomless sex, transactional sex, low socio-economic status, and alcohol and substance use. Though these factors have been well-documented globally, particularly among younger populations, there remains a need to explore specific drivers of the HIV epidemic and most vulnerable populations in specific areas with a high burden of HIV to aid in the formulation of targeted interventions [15–18]. Studies conducted in sub-Saharan Africa on factors associated with HIV acquisition indicate that risk varies widely depending on sociodemographic and behavioral factors, such as sharing needles or having condomless sex. The key risk factors for heterosexual transmission (the dominant mode of acquiring HIV in Africa) are transactional or paid sex, multiple sexual partners, co-infection with sexually transmitted infections (STIs), and lack of male circumcision [19]. Some exposures to HIV carry a much higher risk of transmission than other exposures, but risks can accumulate over time and even relatively low-risk events can contribute to a high cumulative lifetime risk of HIV acquisition. Repeated exposures increase the chances of HIV acquisition compared to a single exposure [20,21]. Certain populations are recognized as having particularly high HIV incidence—including men who have sex with men (MSM), female sex workers (FSWs), and the fisherfolk community—who constitute a small proportion of the general population, but are at an elevated risk of HIV acquisition due to behavioral factors and social marginalization [22–25]. For example, MSM have 26 times higher risk of acquiring HIV than the general population [26]. Additionally, fisherfolk in this region have been shown to experience high mobility, transactional sexual networks, and elevated HIV prevalence, making them an important population in local HIV epidemiology [27]. Understanding HIV incidence among vulnerable groups is critical for efficient targeting of strategies to prevent HIV transmission and acquisition [28–31]. Low socioeconomic status (SES) and its correlates (lower education, poverty, and poor health) characterize many populations in low and middle-income countries such as Kenya. According to the World Bank, Kenya has one of the lowest gross domestic products in the world, with an income of $2,206.10 per capita as of 2024 [32]. Prior studies indicate that SES is differentially associated with HIV acquisition risk. HIV is intertwined in social and economic conditions, as it disproportionately affects those of lower SES. A lack of economic resources is linked to the sexual behaviors that confer HIV risk such as transactional sex [33–38]. Although aggregate incidence estimates are understood relatively well, defining HIV risk by specific locations is required to effectively conduct research of novel prevention strategies among populations most in need of these intervention. This study aimed to define HIV incidence in a cohort in Kisumu County, Western Kenya, and to identify specific factors associated with HIV acquisition. The results can aid in developing strategic, targeted, and effective HIV prevention interventions. Incidence data will also inform selection of potential sites for clinical trials to evaluate HIV vaccines and other prevention products. Methods Study Population and Procedures Between 27 January 2017 and 17 May 2018, we enrolled participants into a non-randomized, observational, prospective study to assess HIV incidence among adults with multiple sexual partners in Kisumu, Kenya [39,40]. Males and females were eligible for enrollment if they were aged 18–35 years, tested negative for HIV, and reported sex with at least two partners in the preceding three months. A small group of people with HIV were also enrolled who satisfied other eligibility criteria in order to mask the HIV status of participants due to HIV-related stigma in the community and to serve as controls for laboratory assays. Participants in the masking group were aware of their HIV status, provided informed consent, received appropriate counseling and linkage to care, and understood that they were being enrolled as controls for laboratory assays. Exclusion criteria included pregnancy, any significant conditions (medical, psychological/psychiatric, or social) that would interfere with study conduct, intent not to reside in Kisumu County for the full study duration, and previous receipt investigational agents that could change HIV risk, such as monoclonal antibodies or candidate HIV vaccines. Determinations regarding significant underlying conditions were made by a principal or sub‑investigator based on clinical judgment following review of each participant’s medical and psychosocial history, rather than a predefined list of conditions. Participants were recruited via community outreach and mobilization activities facilitated by community-based organizations, local ministry of health offices, and community leaders. Targeted recruitment was conducted at locations known to be focal points for activities associated with HIV risk, including bars, markets, fishing villages, and healthcare settings such as HIV testing centers and family planning clinics. An enrollment target of 600 participants without HIV was set based on a hypothesized HIV incidence of 3 cases per 100 person-years. Assuming retention of 85% of participants, 0 cases would need to be observed over 925 person-years in order to conclude with 95% confidence that the true HIV incidence was no less than hypothesized (95% confidence interval 3.1-5.9 cases per 100 person-years). Participants who were lost to follow-up while the study was still open for accrual could be replaced at investigator discretion. After enrollment, follow-up visits were scheduled every 3 months for up to 24 months. Medical history-taking, physical examination, and HIV counseling and testing were performed at each study visit. Behavioral questionnaires were administered to study participants by trained study staff at enrollment and every 6 months. The questionnaires collected information on basic socio-demographic information, general health, sexual activities, and other behaviors. Follow-up of participants was completed on 03 August 2021. Laboratory procedures At study entry and quarterly visits, fingerstick whole blood was tested for HIV according to the Kenyan Ministry of Health guidelines of serial HIV rapid tests using Determine (Abbott Laboratories, Japan) and Fast Response 1-2.0 (Premier Medical Corporation, India) [41]. A third test was used to resolve inconclusive or inconsistent results, such as the HIV-1/2 rapid test or the GenScreen ULTRA HIV Ag-Ab Combo ELISA (Bio-Rad Laboratories, USA). Reactive ELISA underwent HIV confirmation/differentiation (Geenius; Bio-Rad Laboratories, USA) and/or HIV RNA PCR. All testing was performed according to package inserts. Participants with incident HIV were referred for antiretroviral therapy as clinically indicated. Ethics statement This study was reviewed and approved by the Kenya Medical Research Institute Scientific and Ethical Review Unit, Nairobi, Kenya and the Walter Reed Army Institute of Research Institutional Review Board, Silver Spring, Maryland USA. The protocol used for this study complied with International Conference on Harmonization Good Clinical Practice guidelines and was conducted in accordance with the principles described in the Nuremberg Code and the Belmont Report including all federal regulations regarding the protection of human participants as described in 32 CFR 219 and Army Regulation 70–25. All participants and impartial witnesses of illiterate participants provided written informed consent before screening for study eligibility. Statistical analyses Participants included in these analyses had a negative HIV test at enrollment and completed at least one follow-up visit with HIV diagnostic testing. All enrolled participants without HIV who completed at least one follow‑up HIV test contributed person‑time until their last documented negative test, after which they were censored. Observation time was calculated by subtracting the first date with an HIV diagnostic test result from the last date with an HIV diagnostic test result. Behavioral data were collected every six months and, if missing at a particular visit, were carried forward from the preceding visit. If HIV acquisition was detected between visits with behavioral data collection, participants were asked to complete the behavioral questionnaire at the visit when HIV was diagnosed or a separately scheduled visit soon thereafter to minimize participant burden. In the present analyses, if the interval between the visits at which HIV was diagnosed and the behavioral questionnaire was completed was longer than 10 days, data from the previous completed questionnaire closest to the HIV diagnosis date was imputed forwards to better capture behaviors prior to HIV acquisition. Demographic and distributional response data from the screening visit were examined for differences between participants who did and did not acquire HIV using chi-squared tests of association. Subsequent analyses incorporated both static and time-variant data. Static variables were collected at screening/enrollment and included: sex, age, highest education obtained, monthly income, marital status, history of alcohol abuse, history of STI diagnosis and treatment, and age at sexual debut. Variables allowed to be time variant included: having a current spouse or primary sexual partner, having a current secondary sexual partner, condom use with primary partner in the last 3 months, condom use with secondary partner in the last 3 months, number of sexual partners in the last 3 months, having a partner older by 10 + years in the last 3 months, occurrences of binge drinking (defined as the consumption of 5 + alcoholic drinks in 1 day), unwanted sexual events (defined as forced sexual activity, including rape, assault, or coercion) and participation in transactional sex within the last 3 months. HIV incidence rates were calculated overall was disaggregated by year of follow-up in the study. Per-year incidence calculation included participants with at least one valid timepoint collected in that year segment. Person-time was calculated as time between enrollment (in days) and the midpoint between the last visit with a negative HIV test and the visit with a positive HIV test. Due to a clinical pause from the COVID-19 pandemic, some participants had person-time exceeding the originally planned 2 years (or 730 days) of follow-up because their final visit was delayed. Person-time was calculated using the observation days up to the final HIV test, including the COVID-19-pause window. As there were no HIV acquisitions detected during this time, analyses of potential differences between the planned window and extended window were not conducted. Incidence rate confidence limits were calculated using Byar’s method to account for the relatively low case count. Bivariable Cox proportional hazard models were used to assess differential association between variables of interest and HIV acquisition over time. Variables that were significant in the unadjusted bivariable model were included in an adjusted multivariable model except for participant sex, which was forced selected into the multivariate model. Kaplan-Meier cumulative event curves were constructed for variables with P ≤ 0.1 in the bivariable regression models. Statistical analyses were conducted using SAS v9.4 (SAS Institute, Cary, NC). Kaplan-Meier curves were constructed in R (v4.3.1; R Core Team 2023). Results Summary characteristics of study participants From 1072 participants screened for study eligibility, 671 participants were enrolled, including 619 participants without HIV (Fig 1). RV393 Screening, Enrollment, and Follow-up Flowchart. Participants who withdrew, were lost to follow‑up, or died were included through their last HIV‑testing visit. Of the 619 participants without HIV enrolled, 278 (44.9%) were females (Table 1). Enrolled participants had a median age of 21 years (interquartile range [IQR]: 21–28), and the majority were single (65.9%) and had completed primary school or less education (54.1%). The median monthly income was 9000 Kenyan shillings (IQR: 5000–15000). Eleven participants (1.8%) acquired HIV during the 24-month follow-up period, of whom the majority were female (72.7%), aged 30 years and older (36.4%), single or widowed (45.5%), and had completed primary school or less education (72.7%). Most of the participants who acquired HIV (six, 54.5%) reported exchanging sex for money, goods, gifts, or favors. Although all the participants who acquired HIV reported no history of alcohol abuse, six (54.5%) sometimes consumed alcohol before having sex. None of the participants who acquired HIV had a prior history of STI diagnosis or treatment. 10.1371/journal.pone.0349111.t001Table 1Enrollment Sociodemographic and Behavioral Characteristics, by HIV Status at End of Study.Incident HIV caseCharacteristicTotal(N = 619)No(n = 608)Yes(n = 11) P n (%)n (%)n (%)Sex0.0613 Male341 (55.1)338 (55.6)3 (27.3) Female278 (44.9)270 (44.4)8 (72.7)Age (years)0.3655 18-20110 (17.8)108 (17.8)2 (18.2) 21-24223 (36.0)221 (36.3)2 (18.2) 25-29176 (28.4)173 (28.5)3 (27.3) 30-35110 (17.8)106 (17.4)4 (36.4)Marital status0.1888 Married (monogamous, polygamous)141 (22.8)138 (22.7)3 (27.3) Separated or divorced70 (11.3)67 (11.0)3 (27.3) Single or widowed408 (65.9)403 (66.3)5 (45.5)Education level0.2114 Completed primary or less335 (54.1)327 (53.8)8 (72.7) Some secondary or more284 (45.9)281 (46.2)3 (27.3)Monthly income (Ksh)0.7199 ≤9,000313 (50.8)308 (50.9)5 (45.5) >9,000303 (49.2)297 (49.1)6 (54.5) Missing330History of sexually transmitted infection0.5739 No602 (97.3)591 (97.2)11 (100) Yes17 (2.7)17 (2.8)0 (0)History of alcohol abuse0.3212 No569 (91.9)558 (91.8)11(100.0) Yes50 (8.1)50 (8.2)0(0.0)Occurrences of ≥5 drinks in a day in the last 3 months0.1142 0516 (89.7)509 (90.1)7 (70) 1-218 (3.1)17 (3)1 (10) 3-441 (7.1)39(6.9)2 (20) Missing44431Drinking before sex0.3418 Never357 (63.3)352 (63.7)5 (45.5) Sometimes194 (34.4)188 (34)6 (54.5) Always13 (2.3)13 (2.4)0 (0) Missing55550History of non-injectable drug use0.2682 No524 (84.7)516 (84.9)8 (72.7) Yes95 (15.3)92 (15.1)3 (27.3)Number of sexual partners in the last 3 months0.1090 0-1293 (47.7)289 (47.9)4 (36.4) 2-3233 (37.9)230 (38.1)3 (27.3) ≥488 (14.3)84 (13.9)4 (36.4) Missing550Partner sex0.3745 N/A – not sexually active50 (8.2)50 (8.3)0 (0) Male247 (40.3)240 (39.9)7 (63.6) Female297 (48.5)293 (48.7)4 (36.4) Both19 (3.1)19 (3.2)0 (0) Missing660Partner type: spouse0.8431 No373 (60.7)366 (60.7)7 (63.6) Yes241 (39.3)237 (39.3)4 (36.4) Missing550Partner type: girlfriend/boyfriend0.3239 No196 (31.9)194 (32.2)2 (18.2) Yes418 (68.1)409 (67.8)9 (81.8) Missing550Partner type: single-night encounter0.1856 No530 (86.3)522 (86.6)8 (72.7) Yes84 (13.7)81 (13.4)3 (27.3) Missing550Partner type: sex worker0.2714 No594 (96.7)584 (96.8)10 (90.9) Yes20 (3.3)19 (3.2)1 (9.1) Missing550Partner type: coworker0.7006 No606 (98.7)595 (98.7)11 (100) Yes8 (1.3)8 (1.3)0 (0) Missing550Partner type: relative0.8269 No517 (84.2)508 (84.2)9 (81.8) Yes97 (15.8)95 (15.8)2 (18.2) Missing550Partner type: other0.8925 No613 (99.8)602 (99.8)11 (100) Yes1 (0.2)1 (0.2)0 (0) Missing550Currently has primary sexual partner0.8537 No323 (57.3)317 (57.3)6 (54.5) Yes241 (42.7)236 (42.7)5 (45.5) Missing55550Condom use with primary sexual partner0.2309 Never198 (81.5)194 (81.9)4 (66.7) Sometimes29 (11.9)27 (11.4)2 (33.3) Always16 (6.6)16 (6.8)0 (0) Missing3763715Secondary sexual partner0.4637 No172 (28)170 (28.2)2 (18.2) Yes442 (72)433 (71.8)9 (81.8) Missing550Condom use with secondary sexual partner 0.0279 Never41 (9.3)39 (9)2 (22.2) Sometimes160 (36.3)154 (35.6)6 (66.7) Always240 (54.4)239 (55.3)1 (11.1)Missing / No secondary sexual partner1781762Forced to engage in unwanted sexual events 0.0485 No604 (98.4)594 (98.5)10 (90.9) Yes10 (1.6)9 (1.5)1 (9.1) Missing550Exchanged sex for goods or money0.3225 No338 (59.9)333 (60.2)5 (45.5) Yes226 (40.1)220 (39.8)6 (54.5) Missing55550Partner younger than participant by ≥10 years0.8136 No544 (96.5)533 (96.4)11 (100) Yes19 (3.4)19 (3.4)0 (0) Refused1 (0.2)1 (0.2)0 (0) Missing55550Partner older than participant by ≥10 years0.7084 No435 (77.1)426 (77)9 (81.8) Yes129 (22.9)127 (23)2 (18.2) Missing55550Demographic and other characteristics ascertained at enrollment were examined for differences between participants who did and did not acquire HIV using Pearson’s Chi-square test or, in cases with small cell sizes, Fisher’s exact test. All data are presented as n (%). Statistically significant P-values (P ≤ 0.05) are in bold.Ksh, Kenyan shillings; NA, non-applicable; STI, sexually transmitted infection. Enrollment Sociodemographic and Behavioral Characteristics, by HIV Status at End of Study. Demographic and other characteristics ascertained at enrollment were examined for differences between participants who did and did not acquire HIV using Pearson’s Chi-square test or, in cases with small cell sizes, Fisher’s exact test. All data are presented as n (%). Statistically significant P-values (P ≤ 0.05) are in bold. Ksh, Kenyan shillings; NA, non-applicable; STI, sexually transmitted infection. HIV incidence dynamics Table 2 depicts the incidence dynamics in the cohort. A total of 11 incident HIV cases occurred over 1117.9 person-years (PY) resulting in an incidence rate (IR) of 9.84 per 1000 PY (95% confidence interval (CI): 5.22-17.03). Of the 11 participants who acquired HIV, the majority [8] occurred during the first year of follow-up (IR: 13.84 per 1000 PY, 95% CI: 6.53-26.11). Year 2 included the COVID-19 pause (from March to September 2020), however, there were no new incident HIV cases diagnosed after this pause. 10.1371/journal.pone.0349111.t002Table 2Incidence rates of HIV acquisition by study year.Participants whoacquired HIV, nParticipants whodid not acquire HIV, nHIV incidence, rate per 1000 person-years95% Confidence IntervalTotal116089.845.22-17.03Year 1861113.846.53-26.11Year 235555.591.55-14.91Person-time was calculated as time between enrolment (in days) and the midpoint between the last visit with a negative HIV test and the visit with a positive HIV test. Incidence rate confidence limits were calculated using Byar’s method to account for the relatively low case count. Incidence rates of HIV acquisition by study year. Person-time was calculated as time between enrolment (in days) and the midpoint between the last visit with a negative HIV test and the visit with a positive HIV test. Incidence rate confidence limits were calculated using Byar’s method to account for the relatively low case count. Risk factors for HIV acquisition In unadjusted analyses, factors associated with HIV seroconversion included number of sexual partners and forced participation in sexual activity (Table 3). Histories of STI and alcohol abuse were excluded from the bivariable results due to major violations of the proportional hazards assumption, yielding unreliable hazard ratios (HR). Three variables were included in the multivariable Cox regression analysis: sex, number of sexual partners in the last 3 months, and forced to engage in unwanted sexual events. In the multivariable analysis, females appeared to have almost 3 times greater risk of HIV acquisition compared to males, however, this association was not statistically significant (HR: 2.97; 95% CI: 0.76-11.53). Additionally, having 4 or more sexual partners and being forced to participate in sexual activity were associated with trends toward greater risk of HIV acquisition but not statistically significant after controlling for other variables. 10.1371/journal.pone.0349111.t003Table 3Unadjusted and Adjusted Cox proportional hazard models for factors associated with incident HIV.CharacteristicUnadjusted Hazard Ratio(95% CI) P AdjustedHazard Ratio(95% CI) P Sex MaleReferenceReference Female3.44 (0.91-12.98)0.06792.97 (0.76-11.53)0.1162Age (years) 18-20ReferenceReference 21-240.50 (0.07-3.52)0.4829--- 25-290.94 (0.16-5.62)0.9446 ≥301.99 (0.36-10.85)0.4280---Marital status Separated or divorced2.11 (0.43-10.44)0.3611--- Single or widowed0.59 (0.14-2.45)0.4645---Education level Completed primary or lessReferenceReference Some secondary or more0.44 (0.12-1.64)0.2207---Monthly income (Ksh) ≤9000ReferenceReference >90001.21 (0.37-3.95)0.7581---Occurrences of ≥5 drinks in a day in the last 3 months NeverReferenceReference 1-24.38 (0.54-35.58)0.1674--- 3-43.56 (0.74-17.11)0.1136---History of non-injectable drugs NoReferenceReference Yes2.14 (0.57-8.06)0.2616---Currently has primary sexual partner NoReferenceReference Yes1.11 (0.34-3.64)0.8609---Condom use with primary sexual partner NeverReferenceReference Sometimes3.74 (0.69-20.43)0.1277--- Always0 (0−0)0.9953---Currently has secondary sexual partner NoReferenceReference Yes1.90 (0.41-8.81)0.4102Condom use with secondary sexual partner NeverReferenceReference Sometimes1.87 (0.38-9.27)0.4429--- Always0.20 (0.02-2.18)0.1859---Number of sexual partners in the last 3 months 0-1ReferenceReference 2-31.01 (0.23-4.50)0.99231.15 (0.25-5.24)0.8564 ≥44.39 (1.10-17.55) 0.0365 3.44 (0.84-14.15)0.0869Partner type: spouse NoReferenceReference Yes0.88 (0.26-2.99)0.8320---Partner type: girlfriend/ boyfriend NoReferenceReference Yes2.20 (0.48-10.18)0.3132---Partner type: single-night encounter NoReferenceReference Yes3.08 (0.82-11.62)0.0965---Partner type: sex workerNoReferenceReferenceYes3.67 (0.47-28.64)0.2155---Forced to engage in unwanted sexual events NoReferenceReference Yes9.15 (1.17-71.51) 0.0348 6.16 (0.76-49.95)0.0886Exchanged sex for goods or money NoReferenceReference Yes2.02 (0.62-6.63)0.2450---Partner older than participant by ≥10 years NoReferenceReference Yes0.88 (0.19-4.10)0.8756---Statistically significant P-values (P ≤ 0.05) are indicated in bold text. Sex was forced selected into the multivariable model. Variables not included from Table 1 did not meet the proportional hazards assumption.CI, confidence interval; Ksh, Kenyan Shillings. Unadjusted and Adjusted Cox proportional hazard models for factors associated with incident HIV. Statistically significant P-values (P ≤ 0.05) are indicated in bold text. Sex was forced selected into the multivariable model. Variables not included from Table 1 did not meet the proportional hazards assumption. CI, confidence interval; Ksh, Kenyan Shillings. Fig 2 presents the Kaplan-Meier cumulative event curves from the variables with P ≤ 0.1 in unadjusted models. The cumulative incidence curves for sex indicated the strongest differential incidence by sex in the first year of observation. Cumulative incidence for number of partners indicated little material difference between the 0–1 and 2–3 sexual partners in the last 3 months but indicated consistently increased incidence in participants reporting ≥4 partners. Cumulative incidence in participants reporting single night encounters was relatively homogenous in the first 6 months of the observation period but strongly differentiates after 180 days post-enrollment. Kaplan-Meier Cumulative Event Curves for Incident HIV. Kaplan-Meier survival curves were constructed for variables with P ≤ 0.1 in the unadjusted bivariate regression models. Four covariates were examined with Kaplan-Meier curves: partner type-single night encounter (A), number of sexual partners in the last 3 months (B), forced to participate in sexual activity (C), and sex (D). Discussion We observed a modest overall HIV incidence rate compared to prior studies in similar high-risk populations within sub-Saharan Africa. Similar longitudinal cohorts in high‑burden regions have also reported lower‑than‑anticipated HIV incidence, often attributed to a cohort effect of heightened prevention behaviors resulting from study participation as well as intensified HIV prevention efforts in the community, including PEPFAR‑supported interventions. For instance, a prior cohort study among serodiscordant couples in Uganda reported an incidence of 43 per 1000 person-years [42], and other incidence studies among women in South Africa had comparable results of approximately 40 per 1000 person-years [43,44]. Furthermore, a similar prospective cohort study conducted in Mozambique between 2014 and 2017 among adults aged 18–35 reported an incidence of 20.2 per 1000 person-years [45]. These comparisons suggest that the population enrolled in our study, although selected based on behavioral criteria, these measures may not have been optimal correlates of HIV risk or the enrolled population may have benefited from regional HIV prevention efforts, possibly including increased access to testing, education, and prevention services in Kenya [46]. Notably, HIV incidence in our study was highest during the first year of follow-up and declined in subsequent years. This temporal trend may reflect a combination of behavioral and external factors. Participants may have altered their risk behaviors because of repeated counseling, ongoing health education, and HIV risk reduction messaging received at study visits, a phenomenon consistent with a cohort effect seen in longitudinal studies of high-risk populations [47]. Moreover, consistent follow-up may have led to better linkage to prevention services, including condom distribution, STI screening, and HIV pre-exposure prophylaxis (PrEP). Prior analyses from this cohort have shown that almost half of participants expressed interest in PrEP, though only 18% has ever used PrEP prior to enrollment [48]. We theorize that the COVID-19 pandemic, which disrupted daily life, economic activity, and social interaction, may have also contributed to reduced sexual activity or changes in sexual networks, thereby lowering the risk of HIV acquisition in the latter study years [49]. Additionally, individuals who self‑select into longitudinal studies and remain engaged in follow‑up may adopt safer sexual behaviors over time, contributing to declining incidence in later study periods. Although not statistically significant, female participants demonstrated a higher HIV risk compared to their male counterparts. Regional epidemiological data demonstrate that women (particularly adolescent girls and young women) bear a disproportionate burden of HIV in sub-Saharan Africa [5]. This sex disparity has been attributed to factors such as earlier sexual debut, higher rates of transactional sex, limited access to education and health services, and partner dynamics that limit women’s ability to negotiate safer sex [50]. In our study, forced sexual activity was associated with a markedly elevated HIV acquisition, further underscoring the vulnerability of women and the importance of addressing sexual violence as part of comprehensive HIV prevention strategies. Our study also found that having four or more sexual partners and engaging in transactional sex were common behaviors among participants who acquired HIV. These findings align with prior research showing that multiple concurrent partnerships and transactional sex are significant drivers of HIV transmission [51]. However, none of these variables remained statistically significant in the adjusted multivariable model, likely due to the small number of HIV events, which limited statistical power. Prior analyses from this cohort have highlighted heterogeneous patterns of transactional sex (including sex in exchange primarily for money and sex in exchange for money and other necessities) that associated with other risk factors for HIV acquisition such as a higher number of sex partners [52]. There are some limitations of this study to consider. First, the relatively low number of HIV seroconversions restricted the ability to detect statistically significant associations in multivariable analyses and may have led to wide confidence intervals. Second, behavioral data such as number of sexual partners, condom use, and experience of forced sex were self-reported and thus subject to recall and social desirability bias. The 6‑month interval for behavioral data collection, determined by participant‑burden considerations, may have further contributed to this bias. Finally, the COVID-19 pandemic introduced unanticipated interruptions, including extended follow-up times for some participants, which may have influenced both behavior and HIV risk in ways that were not uniformly measurable. Despite these limitations, our findings have important implications for HIV prevention efforts in high-burden settings. In conclusion, while the overall HIV incidence in this cohort was lower than anticipated, the study provides key insights into the temporal dynamics of HIV risk and the behavioral and sex-related factors that may influence transmission. Future research should aim to validate these findings in larger cohorts and assess how best to integrate HIV prevention services into community-based platforms that reach individuals before they acquire infection. 7 Jan 2026 -->PONE-D-25-59538-->-->HIV Incidence Among Sexually Active Young Males and Females in Kisumu County, Western Kenya-->-->PLOS One Dear Dr. Crowell, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.-->--> -->-->Overall, I found your manuscript to be well-organized and well-written. Please examine both reviewers' reports and provide edits and/or answers to each of their comments and questions. --> As part of this process, the journal staff requested a review of previously published RV393 data to ensure this manuscript was not a re-publication of data. I appreciate the specific methodology describing RV393's enrollment, the inclusion of Figure 1, and the disclosure statement regarding the partial presentation of this data at CROI 2025. Please submit your revised manuscript by Feb 21 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. -->If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Darrell Eugene Singer, M.D., M.P.H. Academic Editor PLOS One Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Please include a complete copy of PLOS’ questionnaire on inclusivity in global research in your revised manuscript. Our policy for research in this area aims to improve transparency in the reporting of research performed outside of researchers’ own country or community. The policy applies to researchers who have travelled to a different country to conduct research, research with Indigenous populations or their lands, and research on cultural artefacts. The questionnaire can also be requested at the journal’s discretion for any other submissions, even if these conditions are not met. Please find more information on the policy and a link to download a blank copy of the questionnaire here: https://journals.plos.org/plosone/s/best-practices-in-research-reporting. Please upload a completed version of your questionnaire as Supporting Information when you resubmit your manuscript. 3. One of the noted authors is a group or consortium [RV393 Study Group]. In addition to naming the author group, please list the individual authors and affiliations within this group in the acknowledgments section of your manuscript. Please also indicate clearly a lead author for this group along with a contact email address. 4. We note that you have indicated that there are restrictions to data sharing for this study. For studies involving human research participant data or other sensitive data, we encourage authors to share de-identified or anonymized data. However, when data cannot be publicly shared for ethical reasons, we allow authors to make their data sets available upon request. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Before we proceed with your manuscript, please address the following prompts: a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., a Research Ethics Committee or Institutional Review Board, etc.). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories. You also have the option of uploading the data as Supporting Information files, but we would recommend depositing data directly to a data repository if possible. Please update your Data Availability statement in the submission form accordingly. 5. In the online submission form, you indicated that to request a minimal data set, please contact the Data Coordinating and Analysis Center (DCAC) at PubRequest@hivresearch.org and indicate the RV393 study along with the name of the manuscript. All PLOS journals now require all data underlying the findings described in their manuscript to be freely available to other researchers, either 1. In a public repository, 2. Within the manuscript itself, or 3. Uploaded as supplementary information. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons on resubmission and your exemption request will be escalated for approval. 6. Thank you for stating the following financial disclosure: This work was supported by a cooperative agreement (W81XWH-11-2-0174; W81XWH-18-2-0040) between the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and the U.S. Department of Defense. This research was funded, in part, by the U.S. National Institute of Allergy and Infectious Diseases. Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." If this statement is not correct you must amend it as needed. Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf. 7. Please amend your list of authors on the manuscript to ensure that each author is linked to an affiliation. Authors’ affiliations should reflect the institution where the work was done (if authors moved subsequently, you can also list the new affiliation stating “current affiliation:….” as necessary). 8. One of the noted authors is a group or consortium [RV393 Study Group]. In addition to naming the author group, please list the individual authors and affiliations within this group in the acknowledgments section of your manuscript. Please also indicate clearly a lead author for this group along with a contact email address. 9. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 10. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #1: Yes Reviewer #2: Yes ********** -->2. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #1: Yes Reviewer #2: Yes ********** -->3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #1: Yes Reviewer #2: No ********** -->4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #1: 1. Is the manuscript technically sound, and do the data support the conclusions? Yes, this manuscript was technically sound and supported the conclusions. Overall, well written and put together and I did not identify any large issues. A few comments/questions regarding this section, specifically for the Methods section A) On Page 6 it is listed that exclusion criteria include “significant conditions (medial, psychological/psychiatric, or social) that would interfere with study conduct”. There are then N=24 in Figure 1 who “Did not meet other eligibility requirements”. Are these the same group of individuals? I would recommend clarifying Figure 1 to address this, potentially just with different labeling in the text box. Also, I would suggest that in the methods section that the authors try to clarify what that above statement actually means. Is Medial supposed to be “Medical”? Are there specific, objective Medical or Psychiatric conditions that the authors pre-identified that they thought would interfere with the study conduct or was each individual excluded based on best judgment by a single person or by a group of investigators? I think this part was little vague and could be written more clearly in order to best follow the methods section. B) During the methods section and Figure 1, I was a little confused if the authors were following more of a Per-Protocol or Intention to Treat methodology for the Person-Time calculations as mentions in the statistics section on page 8 and 9 of the draft manuscript. As an example, Figure 1 lists three categories for individuals removed in follow up (decision to withdraw, death, lost to follow up). Were these individuals who were excluded included at all in the analysis if they completed questionnaires and HIV but withdrew, died, or were lost to follow up at the very end of the study (or over the COVID-19 pause mentioned in the paper)? It might be helpful to list just an additional sentence or two clarifying if any of these were used in analysis and if not, why was that decision made (could put later in the manuscript). I was also a little confused about what would happen to participants who initially did not have exclusion criteria but potentially gained exclusion criteria later in the study. As an example, if an individual was not pregnant at screening but after a time period became pregnant, how much of that was used in the analysis for Person-Time calculation? Once again, the method section was very strong and technically sound, but a few areas of clarity might help the manuscript read a little better. 2. Has the statistical analysis been performed appropriately and rigorously? Yes, this manuscript has appropriate and rigorous statistical analysis. I only had a few comments on the statistical analysis section A) It is very clear that authors only gathered behavioral survey data every 6 months (or up to 10 days after the HIV diagnosis) but I did not totally understand why the authors chose every 6 months versus every 3 months with the HIV testing? Was this just a logistical issue because of the burden of the survey? There is nothing wrong with this, but some clarification or justification might be beneficial. I think this is also important because the authors mention “recall and social desirability bias” on page 18, and I feel like adding length between the surveys likely added to this bias. Also, if a subject does test positive for HIV and then submits a survey, there might be a higher likelihood of recall bias if the individual already knows they have been recently diagnosed with HIV. B) On Page 9 of the manuscript, it states “Variables that were significant in the unadjusted bivariable model were included in a fully-adjusted multivariable model except for participant sex”. I would recommend clarifying that the multivariable model adjusts for all the possible categorical variables. I think this is what was done in the statistical analysis, but it was not explicitly clear and could cause some confusion. Another option might be to edit Table 3 so the “Adjusted Relative Risk” column is a little more clear in the title or add this to the subtext you have on Page 15. 3. Have the authors made all data underlying the findings in their manuscript fully available? Yes, I believe all the data is fully available. I had no issues with the section. As mentioned above, it might be beneficial for the authors to clarify a few things in Figure 1 and data analysis in order to improve clarity for any readers; however, I feel like all the findings and data were clearly available. 4. Is the manuscript presented in an intelligible fashion and written in standard English? Yes, overall I felt like the manuscript is very well written, presented clearly, and that the authors did a great job with their discussion section. I had two comments regarding this section A) On page 6 line 86 of the manuscript draft the authors include the word “medial” as an example of a significant condition for exclusion criteria. Is this word intended to be “medical”? B) On page 9 line 150 of the manuscript the authors state that they used “Byers” method for incidence rate confidence interval calculations. Was this meant to be written as “Byar’s” method, which I believe is the recognized standard spelling? This “Byer’s” spelling is also used in Table 2 on page 13 of the draft manuscript. Reviewer #2: Question 1: Yes This is a well-designed prospective cohort study examining HIV incidence among adults with multiple sexual partners in a high-burden setting in Western Kenya. Overall, the study is technically sound and clearly presented. The data support the authors’ primary conclusions, which are presented with humility and are not overreaching. The longitudinal design, frequent HIV testing using what look like pre-established algorithms, and standardized behavioral data collection are appropriate. Laboratory procedures appear rigorous, and outcome ascertainment is well explained. Ethical oversight is strong (both Kenyan and U.S. IRBs). I appreciated the explanation of informed consent procedures. The inclusion of a masking group of participants living with HIV is explained (HIV-related stigma in the community). However, this aspect of the design raises important questions. Perhaps a brief statement clarifying that these participants were aware of their HIV status, received appropriate counseling and linkage to care, and were aware that they were being enrolled as controls would help reassure readers less familiar with this approach. Question 2: Yes The statistical analyses are appropriate for the study design. Incidence rates are calculated using standard person-time methods suitable for rare events, and the authors do a good job of explaining incorporation of pandemic considerations. Cox proportional hazards models are used appropriately, and violations of proportional hazards assumptions are clearly stated. I appreciated that the authors avoid overfitting and interpret adjusted analyses cautiously. The low number of incident HIV infections is an important limitation and is acknowledged. That said, the observed incidence remains higher than national estimates cited in the Background. This raises the question of whether anticipated incidence informed enrollment targets. Power/sample size calculations are not presented, so inclusion of a brief statement describing enrollment rationale or incidence assumptions (if there were any) would help readers better contextualize the study’s power to detect associations (or even whether this was considered in the study design). Several points of clarity could strengthen the manuscript. In the Introduction, the discussion of “assessing the feasibility of future HIV vaccine and therapeutic trials” is somewhat unclear and does not clearly flow into the Results or Discussion. This should either be more explicitly addressed later in the manuscript or removed from the abstract and introduction. My first read of the manuscript was in the “assessing the feasibility” mindset, and I do not think this was an obvious throughline. A smaller point: for those of us less familiar, the description of fisherfolk would benefit from a brief explanation of their unique characteristics, especially if they represent a large portion of the study population. In the Methods and Results, clearer wording would improve readability. For example, line 40: the variable describing unwanted sexual events should explicitly include the term “forced.” It is used in the table, but should be used here as well. By not including the word “forced,” this variable casts a much wider net. You should be clear here what you are implying, which I think is rape, assault, or coercion. Consistent formatting of numbers throughout the Results (particularly lines 171-174) would also improve readability. Consideration could also be given to including literacy in baseline characteristics if these data were collected, though education is used and is probably getting at the same thing. In the Discussion, several interpretations could be sharpened. Comparisons with other incidence studies (lines 220-224) would benefit from consistent use of rates per 1000 person-years. Paragraph 219-228 raises the question of whether there have been similar studies in which incidence was markedly higher, or if low incidence is a persistent limitation in these types of studies. In lines 230-233, it may also be worth noting that individuals who self-select into longitudinal studies and are able to commit to follow-up may be more likely to adopt safer sexual behaviors over time. Additionally, the statement in lines 238-239 is too strong for something not statistically significant. I recommend dropping “This trend is consistent with” (line 239) and starting the sentence with “Regional…”. Question 3: No The authors state that restrictions will apply. They do have appropriate statements for data availability and requests. Question 4: Yes Overall, this is a solid and carefully conducted study that adds useful incidence data from a high-burden setting. The results are well presented, and the discussion is humble and even-handed. The suggested revisions are largely clarifying in nature and would further strengthen the manuscript without altering its main conclusions. ********** -->6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #1: No Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. --> 15 Apr 2026 RESPONSE TO EDITOR AND REVIEWER COMMENTS Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf RESPONSE: Thank you, the style requirements were reviewed and the manuscript was adjusted accordingly. 2. Please include a complete copy of PLOS’ questionnaire on inclusivity in global research in your revised manuscript. Our policy for research in this area aims to improve transparency in the reporting of research performed outside of researchers’ own country or community. The policy applies to researchers who have travelled to a different country to conduct research, research with Indigenous populations or their lands, and research on cultural artefacts. The questionnaire can also be requested at the journal’s discretion for any other submissions, even if these conditions are not met. Please find more information on the policy and a link to download a blank copy of the questionnaire here: https://journals.plos.org/plosone/s/best-practices-in-research-reporting. Please upload a completed version of your questionnaire as Supporting Information when you resubmit your manuscript. RESPONSE: Thank you. The questionnaire has been completed and will be uploaded. 3. One of the noted authors is a group or consortium [RV393 Study Group]. In addition to naming the author group, please list the individual authors and affiliations within this group in the acknowledgments section of your manuscript. Please also indicate clearly a lead author for this group along with a contact email address. RESPONSE: Thank you. The Acknowledgements have been updated as requested. 4. We note that you have indicated that there are restrictions to data sharing for this study. For studies involving human research participant data or other sensitive data, we encourage authors to share de-identified or anonymized data. However, when data cannot be publicly shared for ethical reasons, we allow authors to make their data sets available upon request. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Before we proceed with your manuscript, please address the following prompts: a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., a Research Ethics Committee or Institutional Review Board, etc.). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories. You also have the option of uploading the data as Supporting Information files, but we would recommend depositing data directly to a data repository if possible. Please update your Data Availability statement in the submission form accordingly. RESPONSE: Thank you – We have no restrictions to sharing a de-identified data set. Please data set can now be accessed at https://dataverse.harvard.edu/dataset.xhtml?persistentId=doi:10.7910/DVN/1KECKH . The Data Availability statement will also be revised accordingly. 5. In the online submission form, you indicated that to request a minimal data set, please contact the Data Coordinating and Analysis Center (DCAC) at PubRequest@hivresearch.org and indicate the RV393 study along with the name of the manuscript. All PLOS journals now require all data underlying the findings described in their manuscript to be freely available to other researchers, either 1. In a public repository, 2. Within the manuscript itself, or 3. Uploaded as supplementary information. This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons on resubmission and your exemption request will be escalated for approval. RESPONSE: As noted in the response above, the de-identified data set has been uploaded to a public repository. 6. Thank you for stating the following financial disclosure: This work was supported by a cooperative agreement (W81XWH-11-2-0174; W81XWH-18-2-0040) between the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., and the U.S. Department of Defense. This research was funded, in part, by the U.S. National Institute of Allergy and Infectious Diseases. Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." If this statement is not correct you must amend it as needed. Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf. RESPONSE: Thank you – We confirm that the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. 7. Please amend your list of authors on the manuscript to ensure that each author is linked to an affiliation. Authors’ affiliations should reflect the institution where the work was done (if authors moved subsequently, you can also list the new affiliation stating “current affiliation:….” as necessary). RESPONSE: Thank you – We confirm that an affiliation is linked to each author. 8. One of the noted authors is a group or consortium [RV393 Study Group]. In addition to naming the author group, please list the individual authors and affiliations within this group in the acknowledgments section of your manuscript. Please also indicate clearly a lead author for this group along with a contact email address. RESPONSE: Thank you – The Acknowledgements have been updated as requested. 9. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. RESPONSE: Thank you – The Reviewers made no such request. 10. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. RESPONSE: Thank you, we have reviewed and updated the references to ensure they are current and appropriate. To our knowledge, no cited article has been retracted. Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ________________________________________ 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ________________________________________ 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: No ________________________________________ 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ________________________________________ 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: 1. Is the manuscript technically sound, and do the data support the conclusions? Yes, this manuscript was technically sound and supported the conclusions. Overall, well written and put together and I did not identify any large issues. A few comments/questions regarding this section, specifically for the Methods section A) On Page 6 it is listed that exclusion criteria include “significant conditions (medial, psychological/psychiatric, or social) that would interfere with study conduct”. There are then N=24 in Figure 1 who “Did not meet other eligibility requirements”. Are these the same group of individuals? I would recommend clarifying Figure 1 to address this, potentially just with different labeling in the text box. Also, I would suggest that in the methods section that the authors try to clarify what that above statement actually means. Is Medial supposed to be “Medical”? Are there specific, objective Medical or Psychiatric conditions that the authors pre-identified that they thought would interfere with the study conduct or was each individual excluded based on best judgment by a single person or by a group of investigators? I think this part was little vague and could be written more clearly in order to best follow the methods section. RESPONSE: Thank you for this helpful comment. We have corrected the typographical error. Upon review, 13 participants were excluded for “other eligibility requirements,” rather than 24 as originally presented. These included participation in another HIV prevention study (n = 1), anticipated unavailability for the 24‑month follow‑up period (n = 4), missing primary contact information (n = 1), missing alternative contact information (n = 2), and pre‑existing medical or psychosocial conditions that could interfere with participation (n = 5). These categories were not mutually exclusive. We have updated the Figure 1 and have added a footer to outline the breakdown for those who “Did not meet other eligibility requirements”. Eligibility assessments were performed by a principal or sub investigator, and exclusions were based on clinical judgment, rather than a predefined list of conditions. We have revised the Methods section to clarify this process by adding the following sentence: Determinations regarding significant underlying conditions were made by a principal or sub investigator based on clinical judgment following review of each participant’s medical and psychosocial history, rather than a predefined list of conditions (Lines 93-96). B) During the methods section and Figure 1, I was a little confused if the authors were following more of a Per-Protocol or Intention to Treat methodology for the Person-Time calculations as mentions in the statistics section on page 8 and 9 of the draft manuscript. As an example, Figure 1 lists three categories for individuals removed in follow up (decision to withdraw, death, lost to follow up). Were these individuals who were excluded included at all in the analysis if they completed questionnaires and HIV but withdrew, died, or were lost to follow up at the very end of the study (or over the COVID-19 pause mentioned in the paper)? It might be helpful to list just an additional sentence or two clarifying if any of these were used in analysis and if not, why was that decision made (could put later in the manuscript). I was also a little confused about what would happen to participants who initially did not have exclusion criteria but potentially gained exclusion criteria later in the study. As an example, if an individual was not pregnant at screening but after a time period became pregnant, how much of that was used in the analysis for Person-Time calculation? Once again, the method section was very strong and technically sound, but a few areas of clarity might help the manuscript read a little better. RESPONSE: Thank you for this comment. We used an ITT-style person‑time analysis in which all participants without HIV who completed at least one follow up HIV test after enrollment contributed person time until their last negative HIV test, after which they were censored. Participants who later withdrew, were lost to follow up, or died were included in the analysis for the time they were observed. Participants who developed new conditions during follow up (including pregnancy) were not removed and continued contributing person time. The COVID 19 pause did not affect incidence estimates because no seroconversions occurred during that period. We clarified our approach in the Methods section as follows: All enrolled participants without HIV who completed at least one follow up HIV test contributed person time until their last documented negative test, after which they were censored (Lines 135-137). 2. Has the statistical analysis been performed appropriately and rigorously? Yes, this manuscript has appropriate and rigorous statistical analysis. I only had a few comments on the statistical analysis section A) It is very clear that authors only gathered behavioral survey data every 6 months (or up to 10 days after the HIV diagnosis) but I did not totally understand why the authors chose every 6 months versus every 3 months with the HIV testing? Was this just a logistical issue because of the burden of the survey? There is nothing wrong with this, but some clarification or justification might be beneficial. I think this is also important because the authors mention “recall and social desirability bias” on page 18, and I feel like adding length between the surveys likely added to this bias. Also, if a subject does test positive for HIV and then submits a survey, there might be a higher likelihood of recall bias if the individual already knows they have been recently diagnosed with HIV. RESPONSE: Thank you for this comment. Behavioral questionnaires were administered every 6 months rather than every 3 months primarily due to the need to minimize participant burden within this high mobility, high risk population. We agree that a 6 month interval may increase recall and social desirability bias, as noted in the manuscript, and we have added Submitted filename: Response to Reviewers_RV393 HIV Incid_Resub1 (clean)_signed.pdf 26 Apr 2026 HIV Incidence Among Sexually Active Young Males and Females in Kisumu County, Western Kenya PONE-D-25-59538R1 Dear Dr. Crowell, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Darrell Eugene Singer, M.D., M.P.H. Academic Editor PLOS One Additional Editor Comments (optional): On behalf of PLOS ONE and the reviewers, I thank the authors for addressing all comments and questions with this polished revised manuscript. Reviewers' comments: